Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Patrick Enright
AddedMar 31, 2024
UpdatedMay 31, 2026
Patrick Enright

Patrick Enright

Co-Founder, Longitude Capital

CrunchbaseLinkedIn

Patrick Enright's Career

Longitude Capital
Longitude Capital

Menlo Park, CA, US

Co-Founder
Corcept Therapeutics
Corcept Therapeutics

Menlo Park, CA, US

Board Member· Board
Epirium Bio
Epirium Bio

San Diego, CA, US

Board Member· Board
Orbus Therapeutics
Orbus Therapeutics

Palo Alto, CA, US

Board Member· Board
CuraSen Therapeutics
CuraSen Therapeutics

San Carlos, CA, US

Board Member· Board
Rivus Pharmaceuticals
Rivus Pharmaceuticals

Charlottesville, VA, US

Board Member· Board
Endeavor Biomedicines
Endeavor Biomedicines

Solana Beach, CA, US

Board Member· Board
Cardiodx
Cardiodx

Redwood City, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Patrick Enright's Career

Longitude Capital
Longitude Capital
Investment FirmInvestment Firm452006Menlo Park, CA, US
Co-Founder

Leadership at Longitude Capital

Andrew CleelandAndrew CleelandBoard Member
David HirschDavid HirschCo-Founder
Lisa SuennenLisa SuennenBoard Member
Andrew ElbardissiAndrew ElbardissiBoard Member
Juliet Tammenoms BakkerJuliet Tammenoms BakkerCo-Founder
Marc-Henri GallettiMarc-Henri GallettiCo-Founder

Similar to Longitude Capital

Longwood FundLongwood FundBoston, MA, USest. 2010Longwood FundBoston, MA, US · est. 2010

Longwood Fund Management: A US-based venture capital firm specializing in healthcare and biotech investments.

Investment Firm20
Longevity Vision FundLongevity Vision FundNew York City, NY, USest. 2019Longevity Vision FundNew York City, NY, US · est. 2019

LVF: A venture capital fund investing in disruptive healthcare technologies for longer, healthier lives.

Investment Firm15
Longley CapitalLongley CapitalSan Diego, CA, USest. 2019Longley CapitalSan Diego, CA, US · est. 2019

Longley Capital: A tech-focused investment firm, nurturing visionary ideas to boost enterprise value.

Investment Firm2
The Longevity FundThe Longevity FundSan Francisco, CA, USest. 2011The Longevity FundSan Francisco, CA, US · est. 2011

Longevity Fund: Investing in human longevity through innovative investment solutions.

Investment Firm2
Corcept Therapeutics
Corcept Therapeutics
Public$80.1M2991998Menlo Park, CA, US
Board Member· Board

Leadership at Corcept Therapeutics

David MahoneyDavid MahoneyBoard Member
Gillian CannonGillian CannonBoard Member
Len BakerLen BakerBoard Member
David SingerDavid SingerCo-Founder
Gregg AltonGregg AltonBoard Member
Jim WilsonJim WilsonBoard Member
Epirium Bio
Epirium Bio
Series A$86.4M302008San Diego, CA, US
Board Member· Board

Leadership at Epirium Bio

Alan MaiselAlan MaiselFounder
Josh RichardsonJosh RichardsonBoard Member
Russell J. CoxRussell J. CoxCEO
Paul L. BernsPaul L. BernsBoard Member
Sandy MahatmeSandy MahatmeBoard Member

Similar to Epirium Bio

Epic-BioEpic-BioSouth San Francisco, CA, USGene Therapiesest. 2018Epic-BioSouth San Francisco, CA, US · est. 2018

Epic Bio: Pioneering the new era of gene expression modulation.

Series A · $55M35
Epirus BiopharmaceuticalsEpirus BiopharmaceuticalsBoston, MA, USPharmaceuticals, Therapeuticsest. 2000Epirus BiopharmaceuticalsBoston, MA, US · est. 2000

Boston-based EPIRUS Biopharmaceuticals develops novel treatments for hypothyroidism and immuno-inflammatory diseases globally.

Public · $83.1M73
EpiBiologicsEpiBiologicsSan Mateo, CA, USTargeted Therapiesest. 2022EpiBiologicsSan Mateo, CA, US · est. 2022

EpiBiologics: Pioneering antibody-based therapies targeting disease-driving proteins.

Series A · $73M38
Petri BioPetri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Seed · $255k3
Orbus Therapeutics
Orbus Therapeutics
Series A$55M52012Palo Alto, CA, US
Board Member· Board

Leadership at Orbus Therapeutics

Ernie MarioErnie MarioBoard Member
Michael WassermanMichael WassermanBoard Member
Kurt von EmsterKurt von EmsterBoard Member
Jason LevinJason LevinBoard Member
Bob MyersBob MyersBoard Member

Similar to Orbus Therapeutics

Orphan Star TherapeuticsOrphan Star TherapeuticsNew York City, NY, USTherapiesest. 2017Orphan Star TherapeuticsNew York City, NY, US · est. 2017

Orphan Star Therapeutics: A NY-based biopharmaceutical firm developing therapies for rare diseases.

Series B · $20M5
Orbital TherapeuticsOrbital TherapeuticsCambridge, MA, USMedicines, RNA Therapiesest. 2022Orbital TherapeuticsCambridge, MA, US · est. 2022

Orbital Therapeutics: Advancing global health with innovative RNA-based medicines.

Series A · $270M33
Orpro TherapeuticsOrpro TherapeuticsSan Diego, CA, USBiopharmaceuticalsest. 2006Orpro TherapeuticsSan Diego, CA, US · est. 2006

OrPro Therapeutics, a San Diego-based biopharmaceutical firm, develops inhaled drugs for obstructive pulmonary diseases.

Seed · $4.5M3
Orphion TherapeuticsOrphion TherapeuticsGreat Neck, NY, USGene Therapyest. 2020Orphion TherapeuticsGreat Neck, NY, US · est. 2020

Orphion Therapeutics: Developing innovative gene therapies for rare genetic disorders.

Series A · $5.3M6
CuraSen Therapeutics
CuraSen Therapeutics
Series A$95.9M382016San Carlos, CA, US
Board Member· Board

Leadership at CuraSen Therapeutics

Mehrdad ShamlooMehrdad ShamlooCo-Founder
Kathleen Sereda GlaubKathleen Sereda GlaubBoard Member
Dan JanneyDan JanneyBoard Member
Anthony FordAnthony FordCo-Founder
Robert BoothRobert BoothCo-Founder
Rivus Pharmaceuticals
Rivus Pharmaceuticals

Charlottesville, VA, US

Board Member· Board
Endeavor Biomedicines
Endeavor Biomedicines
Series B$163M242018Solana Beach, CA, US
Board Member· Board

Leadership at Endeavor Biomedicines

Miguel de los RiosMiguel de los RiosCo-Founder
John HoodJohn HoodBoard Member
Andrew LamAndrew LamBoard Member
Bernard DavitianBernard DavitianBoard Member
Monal MehtaMonal MehtaBoard Member
Sandip AgarwalaSandip AgarwalaBoard Member
Cardiodx
Cardiodx
Series B$337.3M1462004Redwood City, CA, US
Board Member· Board

Leadership at Cardiodx

David LevisonDavid LevisonFounder
Brook ByersBrook ByersBoard Member
Ajit SinghAjit SinghBoard Member
Lou LangeLou LangeBoard Member
David L LevisonDavid L LevisonBoard Member

Patrick Enright's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Patrick Enright

Robert HuginRobert HuginBoard Member · CelgeneAndrew ThompsonAndrew ThompsonCo-Founder · Spring Ridge VenturesJason GarlandJason GarlandBoard Member · Acutus MedicalChris KiritsyChris KiritsyBoard Member · HTG Molecular DiagnosticsEric T. SchmidtEric T. SchmidtBoard Member · Relmada TherapeuticsCory RobertsCory RobertsBoard Member · Firsthand